💊 Cardiovascular Drugs: Latest Developments & Pipeline
Cardiovascular drug research is undergoing a significant shift, moving beyond traditional classes to leverage novel mechanisms that target heart failure, hypertension, and atherosclerosis with greater precision and efficacy.
1. Game Changers in Heart Failure (HF)
The treatment paradigm for Heart Failure (both reduced Ejection Fraction (HFrEF) and preserved Ejection Fraction (HFpEF)) has been revolutionized by new drug classes.
SGLT2 Inhibitors (e.g., Dapagliflozin, Empagliflozin):
Function: Originally for Type 2 Diabetes, this class is now standard-of-care for HF regardless of diabetes status.
1 View